Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation

Shinichiro Okamoto, Satoshi Takahashi, Masatoshi Wakui, Akaru Ishida, Ryuji Tanosaki, Yasuo Ikeda, Shigetaka Asano

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We treated 13 patients with morphologically advanced myelodysplastic syndrome using cytosine arabinoside and total body irradiation, followed by allogeneic marrow transplantation from HLA-identical sibling donors. Granulocyte colony-stimulating factor (G-CSF) was added to the preparative regimen to selectively increase chemosensitivity of leukaemic cells and to improve transplant outcome. No regimen-related deaths occurred, and no side- effects related to the addition of G-CSF were observed except for transient mild bone pain. At a median follow-up time of 39 months the projected 5-year disease-free survival and 5-year overall survival were 67.7% and 75.5%, respectively, with only one case showing cytogenetic relapse. The preparative regimen including G-CSF is feasible, and preliminary results seem to be encouraging. However, a larger trial is clearly warranted to evaluate its efficacy.

Original languageEnglish
Pages (from-to)569-573
Number of pages5
JournalBritish Journal of Haematology
Volume104
Issue number3
Publication statusPublished - 1999

Fingerprint

Myelodysplastic Syndromes
Homologous Transplantation
Granulocyte Colony-Stimulating Factor
Bone Marrow Transplantation
Whole-Body Irradiation
Cytarabine
Cytogenetics
Disease-Free Survival
Siblings
Therapeutics
Bone Marrow
Tissue Donors
Transplants
Bone and Bones
Recurrence
Pain
Survival

Keywords

  • Allogeneic bone marrow transplantation
  • Chemosensitization
  • Conditioning
  • G-CSF
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

@article{d0cfb9a7d9cb43688f0d5783d7b81885,
title = "Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation",
abstract = "We treated 13 patients with morphologically advanced myelodysplastic syndrome using cytosine arabinoside and total body irradiation, followed by allogeneic marrow transplantation from HLA-identical sibling donors. Granulocyte colony-stimulating factor (G-CSF) was added to the preparative regimen to selectively increase chemosensitivity of leukaemic cells and to improve transplant outcome. No regimen-related deaths occurred, and no side- effects related to the addition of G-CSF were observed except for transient mild bone pain. At a median follow-up time of 39 months the projected 5-year disease-free survival and 5-year overall survival were 67.7{\%} and 75.5{\%}, respectively, with only one case showing cytogenetic relapse. The preparative regimen including G-CSF is feasible, and preliminary results seem to be encouraging. However, a larger trial is clearly warranted to evaluate its efficacy.",
keywords = "Allogeneic bone marrow transplantation, Chemosensitization, Conditioning, G-CSF, Myelodysplastic syndrome",
author = "Shinichiro Okamoto and Satoshi Takahashi and Masatoshi Wakui and Akaru Ishida and Ryuji Tanosaki and Yasuo Ikeda and Shigetaka Asano",
year = "1999",
language = "English",
volume = "104",
pages = "569--573",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation

AU - Okamoto, Shinichiro

AU - Takahashi, Satoshi

AU - Wakui, Masatoshi

AU - Ishida, Akaru

AU - Tanosaki, Ryuji

AU - Ikeda, Yasuo

AU - Asano, Shigetaka

PY - 1999

Y1 - 1999

N2 - We treated 13 patients with morphologically advanced myelodysplastic syndrome using cytosine arabinoside and total body irradiation, followed by allogeneic marrow transplantation from HLA-identical sibling donors. Granulocyte colony-stimulating factor (G-CSF) was added to the preparative regimen to selectively increase chemosensitivity of leukaemic cells and to improve transplant outcome. No regimen-related deaths occurred, and no side- effects related to the addition of G-CSF were observed except for transient mild bone pain. At a median follow-up time of 39 months the projected 5-year disease-free survival and 5-year overall survival were 67.7% and 75.5%, respectively, with only one case showing cytogenetic relapse. The preparative regimen including G-CSF is feasible, and preliminary results seem to be encouraging. However, a larger trial is clearly warranted to evaluate its efficacy.

AB - We treated 13 patients with morphologically advanced myelodysplastic syndrome using cytosine arabinoside and total body irradiation, followed by allogeneic marrow transplantation from HLA-identical sibling donors. Granulocyte colony-stimulating factor (G-CSF) was added to the preparative regimen to selectively increase chemosensitivity of leukaemic cells and to improve transplant outcome. No regimen-related deaths occurred, and no side- effects related to the addition of G-CSF were observed except for transient mild bone pain. At a median follow-up time of 39 months the projected 5-year disease-free survival and 5-year overall survival were 67.7% and 75.5%, respectively, with only one case showing cytogenetic relapse. The preparative regimen including G-CSF is feasible, and preliminary results seem to be encouraging. However, a larger trial is clearly warranted to evaluate its efficacy.

KW - Allogeneic bone marrow transplantation

KW - Chemosensitization

KW - Conditioning

KW - G-CSF

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0033025246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033025246&partnerID=8YFLogxK

M3 - Article

C2 - 10086796

AN - SCOPUS:0033025246

VL - 104

SP - 569

EP - 573

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -